
Bio-Techne (TECH) Stock Forecast & Price Target
Bio-Techne (TECH) Analyst Ratings
Bulls say
Bio-Techne is projected to achieve $315.0 million in revenues, reflecting a 3% growth compared to the previous quarter, and adjusted earnings are expected to improve to $0.50 per share, an increase from $0.49 a year ago. The company predominantly operates within the protein sciences segment, contributing approximately 75% of its revenue, which underlies its strong position in the life sciences research market. With diversified operations across North America, Europe, the Middle East, and Asia-Pacific, Bio-Techne is well-positioned for sustained growth and resilience in the evolving biotech landscape.
Bears say
Bio-Techne, a Minnesota-based life sciences manufacturer, is facing potential negative impacts on its revenues and gross margins due to the escalation of US tariffs and proposed significant cuts in funding for key US agencies, such as the NIH. The company’s reliance on the US market, which accounts for approximately 55% of its revenue, heightens its vulnerability to these external economic pressures. As a result, there are adjustments to revenue and margin estimates for the upcoming fourth quarter of fiscal year 2025, indicating expectations of slower-than-anticipated performance.
This aggregate rating is based on analysts' research of Bio-Techne and is not a guaranteed prediction by Public.com or investment advice.
Bio-Techne (TECH) Analyst Forecast & Price Prediction
Start investing in Bio-Techne (TECH)
Order type
Buy in
Order amount
Est. shares
0 shares